Changing regulatory landscape of Biotherapeutics and Cell & Gene Therapies
- World Health Organization’s activities in developing guidelines for biotherapeutics and advanced therapy medicinal products (ATMPs) – (keynote)
- National Regulatory Authority and Industry overviews of biosimilar regulatory landscape, key topics (e.g. interchangeability, noncomparable biologics)
- Overview of ATMP regulatory landscape
- Panel Session